RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Emergent BioSolutions Stock

Emergent BioSolutions ROA 2024

Emergent BioSolutions ROA

-0.42

Ticker

EBS

ISIN

US29089Q1058

WKN

A0LC2W

In 2024, Emergent BioSolutions's return on assets (ROA) was -0.42, a 524.17% increase from the -0.07 ROA in the previous year.

Emergent BioSolutions Aktienanalyse

What does Emergent BioSolutions do?

Emergent BioSolutions Inc is a biotechnology company specializing in the development of products for protection against biological threats, infectious diseases, and cancer. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland, USA. Emergent BioSolutions' business model is based on developing and marketing innovative products for the protection of public health and national security. The company aims to respond to known and unknown threats and focus on the changing healthcare needs of society. Emergent BioSolutions operates in four business segments: Biosavérica, Vaccines, Therapeutics, and Contract Manufacturing. Biosavérica is a Latin American subsidiary specializing in the distribution of biological products in Central and South America. Vaccines develops and produces vaccines for infectious diseases such as anthrax, cholera, and typhoid. Therapeutics focuses on the development of anti-infectives and cancer therapeutics. Contract Manufacturing offers services to the biopharmaceutical industry, including the manufacturing, development, and analysis of biopharmaceutical products. Emergent BioSolutions' products include vaccines, antitoxins, antibodies, and therapeutics. One of their most well-known products is BioThrax, an anthrax vaccine used by the US government for defense against biological threats since 2002. Other products include the cholera vaccine Vaxchora, the flu medication FluBlok, and the antibody Anthim used for anthrax. Emergent BioSolutions has partnerships with various governments and organizations worldwide, including the US government, the European Commission, and the World Health Organization. This collaboration aims to ensure that Emergent BioSolutions provides products and services in the areas of national security and public health and enables a rapid response in the event of epidemics and pandemics. In recent years, Emergent BioSolutions has also made several acquisitions to strengthen its business. In 2017, they acquired Cangene Corporation, a company specialized in the manufacture of anti-infectives and antitoxins. In 2019, Emergent BioSolutions acquired PaxVax, a company developing vaccines for infectious diseases, and Adapt Pharma, a company specializing in antidotes for opioid overdose. Emergent BioSolutions is a company focused on innovative research and development, offering products for the protection of public health and national security. The company has experienced significant growth in recent years and strives to adapt to the changing healthcare needs of society. Emergent BioSolutions ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Emergent BioSolutions's Return on Assets (ROA)

Emergent BioSolutions's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Emergent BioSolutions's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Emergent BioSolutions's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Emergent BioSolutions’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Emergent BioSolutions stock

What is the Return on Assets (ROA) of Emergent BioSolutions this year?

The Return on Assets (ROA) of Emergent BioSolutions is -0.42 undefined this year.

What was the ROA of Emergent BioSolutions compared to the previous year?

The ROA of Emergent BioSolutions has increased by 524.17% compared to the previous year.

What consequences do high ROA have for investors of Emergent BioSolutions?

A high ROA is advantageous for investors of Emergent BioSolutions, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Emergent BioSolutions?

A low ROA can be unfavorable for investors of Emergent BioSolutions as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Emergent BioSolutions affect the company?

An increase in ROA of Emergent BioSolutions can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Emergent BioSolutions impact the company?

A reduction in the ROA of Emergent BioSolutions can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Emergent BioSolutions?

Some factors that can influence the ROA of Emergent BioSolutions include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Emergent BioSolutions important for investors?

The ROA of Emergent BioSolutions is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Emergent BioSolutions take to improve ROA?

To improve ROA, Emergent BioSolutions can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Emergent BioSolutions pay?

Over the past 12 months, Emergent BioSolutions paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Emergent BioSolutions is expected to pay a dividend of 0 USD.

What is the dividend yield of Emergent BioSolutions?

The current dividend yield of Emergent BioSolutions is .

When does Emergent BioSolutions pay dividends?

Emergent BioSolutions pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Emergent BioSolutions?

Emergent BioSolutions paid dividends every year for the past 0 years.

What is the dividend of Emergent BioSolutions?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Emergent BioSolutions located?

Emergent BioSolutions is assigned to the 'Health' sector.

Wann musste ich die Aktien von Emergent BioSolutions kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Emergent BioSolutions from 9/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.

When did Emergent BioSolutions pay the last dividend?

The last dividend was paid out on 9/18/2024.

What was the dividend of Emergent BioSolutions in the year 2023?

In the year 2023, Emergent BioSolutions distributed 0 USD as dividends.

In which currency does Emergent BioSolutions pay out the dividend?

The dividends of Emergent BioSolutions are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Emergent BioSolutions stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Emergent BioSolutions

Our stock analysis for Emergent BioSolutions Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Emergent BioSolutions Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.